Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug

American Journal of Managed Care

Volumn 11, Issue 9, 2005, Pages 546-552

  Cheetham, T Craig ^a   Chan, James ^b   Benson, Victor ^c   Richmond, Cathlene ^d   Levin, Eleanor ^e   Campen, David ^e  

^a Pharmacy Analytic Services   (United States)

^b Pharmacy Outcomes Research Group   (United States)

^c KAISER PERMANENTE   (United States)

^d Drug Information Services   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; GENERIC DRUG; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL OBSERVATION; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; CALIFORNIA; DRUGS, GENERIC; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SIMVASTATIN; TREATMENT OUTCOME;

EID: 25444515452     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Randomized trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
2. Shepherd J, Cobbee SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7-22.
8. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
9. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
10. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Full report. September 2002. Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm. Accessed November 2, 2004.
11. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
12. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74:667-673.
13. Shear CL, Franklin FA, Stinnett S, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation. 1992;85:1293-1303.
14. Waters D, Lesperance J, Gladstone P, et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. CCAIT Study Group. Circulation. 1996;94:614-621.
15. Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol. 1995;76:47C-53C.
16. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation. 2000;102:157-165.
17. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med. 1997;336:153-162.
18. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.
19. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM Jr, Mantell G. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther. 1992;14:708-717.
20. Frohlich J, Brun LD, Blank D, et al. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. Can J Cardiol. 1993;9:405-412.
21. Illingworth DR, Bacon S, Pappu AS, Sexton GJ. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 1992;96:53-64.
22. Merck & Co. WSN0. Mevacor (lovastatin) tablets. Product information. June 10, 2002.
23. Merck & Co. WSN0. Zocor (simvastatin) tablets. Product information. February 2, 2004.
24. Korman L, Borysiuk L. Replacing lovastatin with pravastatin: effect on serum lipids and costs. Am J Health Syst Pharm. 1995;52:1078-1082.
25. Fugit RV, Resch ND. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic. Am J Health Syst Pharm. 2000;57:1703-1708.
26. Patel RJ, Gray DR, Pierce R, Jafari M. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center. Am J Manag Care. 1999;5:465-474.
27. Ito MK, Lin JC, Morreale AP, et al. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol. Am J Health Syst Pharm. 2001;58:1734-1739.
28. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003;163:688-692.
29. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572.